San Diego – The US Food and Drug Administration’s (FDA) top biologics official said the proposed Promising Pathways Act would lower the bar for approving treatments for rare diseases and that the ...
More than one-third of accelerated approval applications do not meet their original confirmatory trial dates, and four drug applications were more than 5 years past their confirmatory trial deadlines, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results